ARS Pharmaceuticals, Inc. (SPRY) Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months

ARS Pharmaceuticals, Inc. Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months

ARS Pharmaceuticals, Inc. (SPRY) had Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months of $1.10 million as of 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Rolling Maturity

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths · last filed 2026-08-13

• 2026-06-30: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $1.10M.
• 2026-03-31: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $1.10M.
• 2025-12-31: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $1.10M.
• 2025-09-30: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $1.10M.